GlassScriptPhysician profile
Saresh M Akmal
NPI 1972130243
$1,150.21
in general payments reported to CMS, 2019-2025
17 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $425 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Entertainment: $13.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.30 |
| Entertainment | $13.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.25 | 2023-2025 | Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.45 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $88.80 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $60.68 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $55.15 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $54.98 | 2023-2024 | Airsupra |
| Lilly USA, LLC | $51.96 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $34.72 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $34.37 | 2024-2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $33.90 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.18 | 2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $25.57 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.42 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $16.69 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $14.15 | 2024 | Nuzyra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.03 | 2023 | Rexulti |
| Optos, INC. | $13.91 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saresh Akmal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.